ArticleEye (London, England)2016
Licence to save: a UK survey of anti-VEGF use for the eye in 2015.
Article in Eye (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.The Cochrane database of systematic reviews · 2024Pooled it
- Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.BMC ophthalmology · 2020Pooled it
- A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.Eye (London, England) · 2017Pooled it
- Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- The disparity between funding for eye research vs. the high cost of sight-loss in the UK.Eye (London, England) · 2023Article
- Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022Review
- Harnessing the Neuroprotective Behaviors of Müller Glia for Retinal Repair.Frontiers in bioscience (Landmark edition) · 2022Review
- Off-label use of bevacizumab for wet age-related macular degeneration in Europe.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Review
- Bevacizumab: a new way of doing business. Part 2.Eye (London, England) · 2019Article
- Exploring factors predicting changes in patients' expectations and psychosocial issues during the course of treatment with intravitreal injections for wet age-related macular degeneration.Eye (London, England) · 2018Article
- Comment on 'Licence to save: a UK survey of anti-VEGF use for the eye in 2015'.Eye (London, England) · 2018Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.